Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53
Go back to Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53| SAREPTA THERAP (NASDAQ: SRPT) | Delayed: 20.11 -0.56 (2.71%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $20.67 | 52 Week High | $63.73 | |||
| Open | $20.63 | 52 Week Low | $8.00 | |||
| Day High | $20.74 | P/E | N/A | |||
| Day Low | $19.62 | EPS | $-5.69 | |||
| Volume | 6,292,416 | |||||
